You are here

  • Home
  • Archive
  • Volume 14, Issue 11
  • Pembrolizumab as adjuvant therapy in a patient with Lynch syndrome with synchronous mixed clear cell carcinoma of ovarian origin and endometroid endometrial carcinoma

Article metrics

Article menu
Download PDFPDF
Case report
Pembrolizumab as adjuvant therapy in a patient with Lynch syndrome with synchronous mixed clear cell carcinoma of ovarian origin and endometroid endometrial carcinoma

 

Online download statistics by month:

Online download statistics by month: November 2021 to April 2024

AbstractFullPdf
Nov 20211300156
Dec 20217951313
Jan 20222531412
Feb 202218747
Mar 20221161110
Apr 202287510
May 2022110411
Jun 2022140312
Jul 20224115
Aug 2022115312
Sep 2022157812
Oct 2022101513
Nov 202273517
Dec 2022104118
Jan 202334114
Feb 202368017
Mar 202383617
Apr 202367114
May 20236319
Jun 20237519
Jul 20235366
Aug 2023102512
Sep 20234511
Oct 20233112
Nov 20233423
Dec 20233903
Jan 20243511
Feb 20245920
Mar 20242042
Apr 2024600
Total4393124268